|
|
No.39 Shangdi Xi Rd
Haidian District, Beijing 100085 China
phone:86-10-82890088
fax:86-10-62966910
|
|
| Symbol |
SVA |
| Exchange |
AMEX |
| Founded |
2009 |
| Employees |
115 |
|
|
| www.sinovac.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Development of treatments for infectious illnesses |
|
| Management |
| Mr. Weidong Yin, General Manager of Sinovac Biotech Co., Ltd., CEO of Sinovac Biotech Ltd.; Mr. Jiansan Zhang, Vice General Manager of Sinovac Biotech Co., Ltd.; Ms. Nan WANG, Vice General Manager of Sinovac Biotech Co., Ltd.; Mr. Changju FU, Vice President; Ms. Xuejie GONG, Senior Manager |
| |
|
|
|
|
|
|
|
| Keywords |
| H1N1 influenza vaccine, PANFLU.1, hepatitis A, seasonal influenza, pandemic influenza |
|
|
|
| Description |
|
Sinovac Biotech Ltd. (also known in China as Beijing Kexing Bioproducts) specializes in the research,development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and ìSARSî. Sinovac is one of the leading emerging biotechnology companies in China. Working closely with Chinese public health officials, Sinovac focuses on manufacturing and marketing human-use vaccines and related products, and currently markets its vaccine for Hepatitis A. Sinovac is the first and currently the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS. |
|
| Products / Services |
Healive, Inactivated Hepatitis A Vaccine, Bilive, Combined Hepatitis A and Hepatitis B Vaccine
|
|
| Technology / Differentiation |
| Healive can provide protection from Hepatitis A for more than 20 years |
|
| Market / Customers |
China
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
